<?xml version="1.0" encoding="UTF-8"?>
<p id="p0130">Two previous trials of systemic corticosteroids to address the high cytokine load did not improve mortality and instead caused a delay in viral clearance (
 <xref rid="b0010" ref-type="bibr">Arabi et al., 2018</xref>, 
 <xref rid="b0385" ref-type="bibr">Stockman et al., 2006</xref>). That said, a new clinical trial of methylprednisolone has recently been approved to determine whether COVID-19 cases respond (
 <xref rid="b0200" ref-type="bibr">Harrison, 2020</xref>). Switching to short-term, moderate-dose regimens of corticosteroids, combined with immunoglobins, improves oxygenation (
 <xref rid="b0465" ref-type="bibr">Zhou et al., 2020</xref>).
</p>
